AI Drug Discovery Breakthrough: First AI-Designed Cancer Drug Enters Phase 3
Insilico Medicine's AI-designed cancer drug enters Phase 3 trials, moving AI pharma from proof of concept to commercialization.
AI pharma hit a milestone: Insilico Medicine's AI-designed cancer drug ISM-5026 officially entered Phase 3 clinical trials — the world's first cancer drug whose target was discovered and whose molecular structure was designed entirely by AI to reach late-stage trials.
ISM-5026 targets a rare solid-tumor target that AI discovered by analyzing hundreds of thousands of papers and genomic data — something traditional methods could hardly find in a reasonable timeframe. From target discovery to candidate selection took just 18 months, versus the usual 5-7 years.
Phase 2 data showed an objective response rate of 48% with good safety. AI pharma companies including Recursion, Exscientia and China's XtalPi also have multiple pipelines in clinical stages. The industry expects AI to cut new-drug development timelines by 60% before 2030.
This is an original analysis by the AI Tools Daily editorial team, based on publicly available information. Opinions are for reference only.